Get the Stockscreener App
31.61
3.20%
0.98
After Hours:
31.61
Tg Therapeutics Inc stock is traded at $31.61, with a volume of 1.53M.
It is up +3.20% in the last 24 hours and down -6.17% over the past month.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
See More
Previous Close:
$30.63
Open:
$30.61
24h Volume:
1.53M
Relative Volume:
0.78
Market Cap:
$5.02B
Revenue:
$264.79M
Net Income/Loss:
$-14.36M
P/E Ratio:
-287.36
EPS:
-0.11
Net Cash Flow:
$-28.11M
1W Performance:
-5.39%
1M Performance:
-6.17%
6M Performance:
-13.18%
1Y Performance:
-5.33%
1-Day Range:
$30.58
$31.79
1-Week Range:
$30.54
$33.61
52-Week Range:
$25.28
$46.48
Tg Therapeutics Inc Stock (TGTX) Company Profile
Name
Tg Therapeutics Inc
Sector
Industry
Phone
(212) 554-4484
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
31.61 | 4.86B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.13 | 109.90B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.67 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
473.29 | 61.42B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
921.80 | 56.36B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.78 | 44.06B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Resumed | H.C. Wainwright | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Oct-29-24 | Initiated | TD Cowen | Buy |
| Aug-02-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-26-23 | Resumed | Jefferies | Buy |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-19-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-01-20 | Initiated | JP Morgan | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Initiated | Evercore ISI | Outperform |
| Jan-17-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Sep-25-18 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-01-17 | Resumed | B. Riley FBR, Inc. | Buy |
| Nov-14-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-17 | Initiated | Jefferies | Buy |
| Mar-06-17 | Reiterated | FBR & Co. | Outperform |
| Oct-06-16 | Resumed | Brean Capital | Buy |
| May-27-16 | Initiated | SunTrust | Buy |
| Dec-01-15 | Initiated | FBR Capital | Outperform |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| Aug-12-15 | Resumed | H.C. Wainwright | Buy |
| Jun-19-15 | Reiterated | Brean Capital | Buy |
| Dec-11-14 | Reiterated | ROTH Capital | Buy |
| Dec-10-14 | Reiterated | ROTH Capital | Buy |
View All
Tg Therapeutics Inc Stock (TGTX) Latest News
Is TG Therapeutics Inc. (NKB2) stock nearing a technical breakout2025 Trading Recap & Verified Swing Trading Watchlists - Newser
Why TG Therapeutics Inc. (NKB2) stock stays resilient2025 Analyst Calls & Fast Entry High Yield Stock Tips - Newser
TG Therapeutics (TGTX) Earnings Date and Reports 2026 - MarketBeat
TG Therapeutics (TGTX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Price-Driven Insight from (TGTX) for Rule-Based Strategy - news.stocktradersdaily.com
Is TG Therapeutics Inc NKB2 a good long term investmentGrowth Stock Opportunities & Affordable Investment Portfolio - earlytimes.in
Can Clinical Progress Updates Boost TG Therapeutics' Value in 2025? - Yahoo Finance
TG Therapeutics CEO Michael S. Weiss to Speak at 8th Annual Evercore Healthcare Conference - Quiver Quantitative
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference - The Manila Times
Why TG Therapeutics Inc. stock remains on watchlists2025 Volatility Report & Stepwise Trade Execution Plans - BỘ NỘI VỤ
TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit - Sahm
TG Therapeutics (TGTX) Is Up After Raising 2025 Revenue Guidance Has the Growth Story Strengthened? - Sahm
Can TG Therapeutics Inc. stock surprise with earnings upsideEarnings Trend Report & Fast Entry High Yield Stock Tips - moha.gov.vn
TG Therapeutics TGTX Q3 2025 Earnings Transcript - Nasdaq
TG Therapeutics, Inc. (TGTX) Stock Forecasts - Yahoo Finance
Director At TG Therapeutics Sells $162K Of Stock - Benzinga
TG Therapeutics Director Sells Shares to Cover Tax Obligations - TradingView
Dir Echelard Sells 5,000 ($162.9K) Of TG Therapeutics Inc [TGTX] - TradingView
TGTX Form 4: Director Yann Echelard stock sale and holdings - Stock Titan
What macro factors could drive TG Therapeutics Inc. (NKB2) stock higherJuly 2025 Sector Moves & Breakout Confirmation Alerts - newser.com
What insider purchases suggest about TG Therapeutics Inc. (NKB2) stockQuarterly Portfolio Report & Smart Investment Allocation Insights - newser.com
Will TG Therapeutics Inc. stock outperform tech sector in 2025Trade Signal Summary & Daily Oversold Stock Bounce Ideas - newser.com
TG Therapeutics Makes 2025 Deloitte Technology Fast 500 List of America's Fastest-Growing Companies - MarketScreener
Why TG Therapeutics Inc. (NKB2) stock trades below fair valueJuly 2025 Institutional & Momentum Based Trading Ideas - newser.com
TG THERAPEUTICS INC (1TGTX.MI) Stock Price, News, Quote & History - Yahoo! Finance Canada
TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies - The Globe and Mail
TG THERAPEUTICS INC (1TGTX.MI) stock price, news, quote and history - Yahoo Finance UK
(TGTX) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Is TG Therapeutics Inc. stock oversold or undervaluedGap Up & Low Risk High Win Rate Stock Picks - newser.com
Will TG Therapeutics Inc. stock benefit from commodity pricesJuly 2025 Outlook & Consistent Profit Alerts - newser.com
Can TG Therapeutics Inc. stock resist market sell offs2025 Performance Recap & Advanced Swing Trade Entry Plans - newser.com
Is it time to cut losses on TG Therapeutics Inc.July 2025 Outlook & Precise Trade Entry Recommendations - newser.com
TG Therapeutics Ranks 27th on Deloitte's Technology Fast 500 for 2025 - Quiver Quantitative
Tools to assess TG Therapeutics Inc.’s risk profile2025 Institutional Moves & Daily Stock Momentum Reports - newser.com
Will TG Therapeutics Inc. (NKB2) stock benefit from commodity supercycleJuly 2025 Recap & Weekly Market Pulse Alerts - newser.com
Tg Therapeutics Inc Stock (TGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):